Skip to content

Distribution characteristics of visceral multistage vascular calcification and its predictive value for death risk in hemodialysis patients

Distribution characteristics of visceral multistage vascular calcification and its predictive value for death risk in hemodialysis patients

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000040842
Enrollment
Unknown
Registered
2020-12-11
Start date
2020-12-01
Completion date
Unknown
Last updated
2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vascular calcification

Interventions

Gold Standard:Clinical outcome
Index test:Mortality&#32
risk&#32
prediction&#32
model&#32
for&#32
hemodialysis&#32

Sponsors

Zhongda Hospital, Southeast University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Project 1: Age >= 18 years; dialysis duration >= 6 months; dialysis 3 times/week, 4 hours/time, using low molecular heparin as anticoagulant; CT scan of chest, abdomen and pelvis was performed during 2015.01.01-2017.09.30. Project 2: Age >= 18 years; capable people who agree to participate in the study and sign informed consent; dialysis duration=6 months; dialysis 3 times/week, 4 hours/time, using low molecular heparin as anticoagulant.

Exclusion criteria

Exclusion criteria: Project 1: Being participating in other interventional studies during follow-up; women who are pregnant/lactant when being conducted CT scan; having malignancy, liver cirrhosis, congestive heart failure, congenital heart disease(NYHA stage 3/4), rheumatic heart disease and other life-threatening diseases when being conducted CT scan. Project 2: Being participating in other interventional studies; women who are pregnant/lactant or have a plan for pregnancy/ lactation during follow-up; having malignancy, liver cirrhosis, congestive heart failure, congenital heart disease(NYHA stage 3/4), rheumatic heart disease and other life-threatening diseases.

Design outcomes

Primary

MeasureTime frame
mortality;SEN, SPE, ACC, AUC of ROC, PV+, PV-;

Countries

China

Contacts

Public ContactXiaoliang Zhang

Zhongda Hospital, Southeast University

tonyxlz@163.com+86 13852290358

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026